SunBio

Founded in 1997, SunBio is a biomaterials and pharmaceutical company specializing in PEGylation technology that moved its listing from KONEX to KOSDAQ in 2022.

Its business is organized around three pillars: direct production and sale of PEG derivative materials, exclusive supply of biosimilar raw materials paired with royalty income, and licensing-out of its own pipeline.

The company operates an EMA-certified GMP facility with a library of more than 200 PEG derivative products and is in the process of consolidating production into a new GMP plant completed in 2024.

Its two main applied products are a pegfilgrastim biosimilar for chemotherapy-induced neutropenia and MucoPEG, a xerostomia treatment, with the company supplying its core raw material mPEG-PAL to India's Intas Pharmaceuticals and collecting a 5% royalty on the finished product's net sales.

That biosimilar was approved and sold in Europe (as Pelgraz) and Canada (as Lapelga) starting in 2018, later in Australia and Mexico, and in June 2026 received final US FDA marketing approval under the name Ennumo, extending its reach into most major pharmaceutical markets.

MucoPEG received US FDA marketing clearance in 2019, but licensing negotiations with global pharmaceutical companies had remained at an introductory stage because the company had not secured a US composition patent.

Artificial blood candidate SBX, an oxygen carrier built on hybrid pegylation technology, has completed preclinical toxicity testing at Charles River Laboratories in the US and is now undergoing animal efficacy testing including hemorrhage and transfusion models.

More recently, the company has also been applying its PEG-based material technology to solid electrolyte development for lithium secondary batteries, extending pipeline diversification beyond its core raw-material business.

Consolidated revenue rose from KRW 7.42 billion in 2022 to KRW 12.29 billion in 2023, fell back to KRW 8.68 billion in 2024, and then climbed to KRW 13.67 billion in 2025, the highest level in the past four years.

The operating profit trajectory has been even more volatile: from a KRW 190 million profit (2.6% margin) in 2022, it jumped to KRW 5.19 billion (42.2% margin) in 2023, swung to an operating loss of KRW 533 million (-6.1% margin) in 2024, and then recovered to a KRW 5.04 billion profit (36.8% margin) in 2025.

Net income attributable to owners followed a similarly uneven path: KRW 869 million in 2022, KRW 4.61 billion in 2023, a loss of KRW 104 million in 2024, and KRW 2.79 billion in 2025.

On a quarterly basis, Q2 2025 posted revenue of KRW 1.72 billion and a modest operating profit of KRW 118 million, yet still recorded a net loss of KRW 1.19 billion, indicating that non-operating items weighed heavily on the bottom line that quarter.

Results then improved markedly in Q3 2025 (revenue KRW 4.25 billion, operating profit KRW 1.62 billion, net income KRW 1.28 billion) and Q4 2025 (revenue KRW 4.68 billion, operating profit KRW 2.11 billion, net income KRW 2.09 billion).

However, Q1 2026 revenue fell sharply from the prior quarter to KRW 1.29 billion and operating profit narrowed to KRW 458 million, a decline attributed to improving product quality and aggressive pricing from Chinese competitors along with delays in US approval and licensing tied to the lack of a US patent.

Q2 2026 revenue recovered to KRW 2.24 billion but operating profit was only KRW 284 million, a lower margin than in Q1, while net income of KRW 631 million came in well above the operating profit figure.

Over the trailing four quarters (Q3 2025 through Q2 2026), cumulative net income attributable to owners totaled KRW 4.31 billion, again underscoring the substantial quarter-to-quarter dispersion in results.

The PEG materials industry is expected to see moderate growth centered on pharmaceutical and medical pegylation demand; market research cited in the company's regulatory filings estimated the PEG materials market at roughly USD 4.1 billion in 2020, with a projected compound annual growth rate of 9.6% from 2021 to 2027.

However, the size of the market specifically for PEG derivative materials is not separately tracked, since a substantial portion of the broader PEG market is used as additives or excipients.

A notable recent shift in the industry has been the improving quality and aggressive pricing of Chinese competitors, which was cited as a factor behind SunBio's Q1 2026 earnings slowdown.

At the same time, there have been positive developments on the regulatory front: partner Intas Pharmaceuticals' pegfilgrastim biosimilar received final US FDA marketing approval in June 2026, extending its sales footprint into the world's largest pharmaceutical market, an event that could also affect SunBio's raw-material supply and royalty income structure.

Newer pipeline candidates such as the artificial blood program remain at the preclinical stage and must clear multiple hurdles, including clinical entry and regulatory approval, before commercialization.

Competitively, SunBio holds a niche position as an exclusive raw-material supplier to a specific large finished-product manufacturer, though the rise of Chinese producers appears to be gradually increasing the substitutability of that raw-material supply chain.

The nearest catalyst is that partner Intas Pharmaceuticals' pegfilgrastim biosimilar Ennumo received final US FDA marketing approval in June 2026, with the company stating that expanded raw-material supply and increased royalty income are expected to contribute to future growth and profitability.

However, when and to what extent US market sales will actually flow into the financial statements remains unconfirmed.

MucoPEG's new US continuation patent filing in July 2026 could lay the groundwork for licensing negotiations with global pharmaceutical companies that had stalled due to the lack of US patent protection, making the progress of that patent examination and any subsequent licensing agreement the next milestones to watch.

The company has also completed a Hong Kong marketing-approval application for MucoPEG and is pursuing global joint research related to its CloudPEG technology as part of efforts to strengthen its market position.

Artificial blood candidate SBX has completed preclinical toxicity testing at Charles River Laboratories in the US and is now in animal efficacy testing, with media reports indicating an IND filing is targeted for 2027.

Building a mass-production system through the new plant's operation is an ongoing task aimed at expanding raw-material production capacity. That said, a resurgence of intensified Chinese competition, as seen in Q1 2026, could delay how quickly these growth catalysts show up in the financial results.